Last reviewed · How we verify
Tumor necrosis factor alpha — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tumor necrosis factor alpha (Tumor necrosis factor alpha) — OncoCareClinic 308 Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tumor necrosis factor alpha TARGET | Tumor necrosis factor alpha | OncoCareClinic 308 Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tumor necrosis factor alpha CI watch — RSS
- Tumor necrosis factor alpha CI watch — Atom
- Tumor necrosis factor alpha CI watch — JSON
- Tumor necrosis factor alpha alone — RSS
Cite this brief
Drug Landscape (2026). Tumor necrosis factor alpha — Competitive Intelligence Brief. https://druglandscape.com/ci/tumor-necrosis-factor-alpha. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing